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Abstract
Background: Diabetes can lead to serious microvascular complications such as proliferative diabetic retinopathy
(PDR), which results in severe vision loss. The diabetes-induced alterations in the vitreous protein composition in
diabetic patients with PDR may be responsible for the presence of PDR. The vitreous humour can be utilised in a
variety of studies aimed toward the discovery of new targets for the treatment or prevention of PDR and the
identification of novel disease mechanisms. The aim of this study was to compare the protein profile of vitreous
humour from diabetic patients with PDR with that of vitreous humour from normal human eyes donated for
corneal transplant.
Results: Vitreous humour from type 2 diabetic patients with PDR (n = 10) and from normal human eyes donated
for corneal transplant (n = 10) were studied. The comparative proteomic analysis was performed using two-
dimensional fluorescence difference gel electrophoresis (2-D DIGE). Differentially produced proteins (abundance
ratio > 2 or < -2, p < 0.01) were identified by matrix-assisted laser desorption ionisation time-of-flight mass
spectrometry (MALDI-TOF MS) and MALDI-TOF tandem mass spectrometry. A total of 1242 protein spots were
detected on the 2-D master gel of the samples, and 57 spots that exhibited statistically significant variations were
successfully identified. The spots corresponded to peptide fragments of 29 proteins, including 8 proteins that
increased and 21 proteins that decreased in PDR. Excluding the serum proteins from minor vitreous haemorrhage,
19 proteins were found to be differentially produced in PDR patients compared with normal subjects; 6 of these
proteins have never been reported to be differentially expressed in PDR vitreous: N(G),N(G)-dimethylarginine
dimethylaminohydrolase 1 (DDAH 1), tubulin alpha-1B chain, gamma-enolase, cytosolic acyl coenzyme A thioester
hydrolase, malate dehydrogenase and phosphatidylethanolamine-binding protein 1 (PEBP 1). The differential
production of pigment epithelium-derived factor (PEDF) and clusterin was confirmed by Western blot analysis.
Conclusions: These data provide an in-depth analysis of the human vitreous proteome and reveal protein
alterations that are possibly involved in the pathogenesis of PDR. Further investigation of these special proteins
may provide potential new targets for the treatment or the prevention of PDR.
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Background
Proliferative diabetic retinopathy (PDR), a serious eye
complication of diabetes, is characterised by a pathologi-
cal process that includes capillary occlusion, tissue
ischaemia, neovascularisation, increased vascular perme-
ability, and the breakdown of the blood-retinal barrier
(BRB) [1]. Subsequently, blindness can result from
fibrovascular proliferation, vitreous haemorrhage, trac-
tional retinal detachment, and the development of neo-
vascular glaucoma (NVG) in PDR [2].
Although the management of risk factors, including
hyperglycemia, hyperlipidemia, and hypertension, has
been shown to ameliorate diabetes-induced vision loss,
the exact pathophysiological mechanisms that are
involved in this process remain to be elucidated. Whereas
the role of high blood glucose has been suggested to be
the primary catalyst for the biomolecular and cellular
changes seen in the retina, less is known regarding the
intraocular biochemical changes associated with the
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esis of PDR.
Because the vitreous contacts the retina, the physiolo-
gical and pathological conditions of the retina affect the
protein components in the vitreous. The vitreous pro-
vides a means of indirectly exploring the events that are
taking place in the retina. Previous reports of vitreous
proteins in PDR used the conventional enzyme linked
immunosorbent assay (ELISA) method [3-5]. In these
studies, however, only a certain set of targeted proteins
from vitreous samples were identified because the
amount of available vitreous was limited, which makes it
difficult to evaluate the changes in the vitreous protein
profiles and to identify novel marker proteins of PDR
pathogenesis. Currently, modern proteomic technologies
have the advantage of facilitating the simultaneous ana-
lysis and identification of large numbers of proteins.
Recent advances in proteome analysis methods have
allowed the further exploration and acquisition of vitr-
eous protein profiles [1,6-8]. In the last few years, pro-
teomics has been applied to explore proteins which
were differentially expressed in patients with prolifera-
tive diabetic retinopathy and in nondiabetic patients
[9-14]. Previous studies have identified some proteins
that are differentially expressed in the vitreous of PDR
patients. Many of the proteins are involved in such pro-
cesses as angiogenesis, cellular proliferation, acute phase
response, vascular permeability changes, and oxygen-
induced vessel loss [7,13]. These studies involved the
use of vitreous from non-diabetic patients with macular
hole (MH) or macular epiretinal membrane (MEM) as
control groups. However, these ocular diseases may
have affected the vitreous protein profiles. Therefore, in
an attempt to obtain “normal control” samples, we used
eyes donated for corneal transplant without any known
ocular diseases as a control group.
The technique of two-dimensional fluorescence differ-
ence gel electrophoresis (2-D DIGE) provides an accurate
quantitative comparison of two groups of samples, allow-
ing the identification of proteins whose levels differ sig-
nificantly between the two conditions [6]. No previous
quantitative proteomic comparison of vitreous humour
from type 2 diabetic patients with PDR with that from
normal human eyes donated for corneal transplant has
been reported. We used 2-D DIGE to perform the quan-
titative proteomic comparison. Matrix-assisted laser des-
orption ionisation time-of-flight mass spectrometry
(MALDI-TOF MS) and MALDI-TOF/TOF MS/MS were
used for protein identification; MS/MS techniques pro-
vide additional amino acid data for selected peptides and
allow for extremely accurate protein identifications [15].
Some of the proteins that were differentially produced in
the vitreous from diabetic patients with PDR and from
normal human eyes donated for corneal transplant were
confirmed by Western blot analysis.
Results
2-D DIGE
The mean protein concentration in the vitreous was sig-
nificantly higher in patients with PDR than in controls
(11.5 vs. 4.32 μg/μl). A representative picture of an over-
l a yo ft h r e ed y es c a ni m a g e s ,C y 2 ,C y 3 ,a n dC y 5 ,i s
shown in Figure 1. Proteins in the pH range applied in
this experiment (pH = 3-10) and in the molecular
weight range of approximately 14 to 97 kDa were
resolved.
A total of 1242 protein spots were detected in gel 1,
1132 spots were detected in gel 2, and 1028 spots were
detected in gel 3. The gel with the greatest number of
spots was automatically assigned as the master gel by the
DeCyder software. A total of 70 protein spots showed
highly significant changes in the expression levels com-
pared with the control group (abundance ratio > 2 or <
-2, p < 0.01). Each spot of interest was excised from the
preparative gel and analysed by MALDI-TOF MS and
MS/MS after in-gel tryptic digestion.
Identified protein lists from MALDI-TOF MS and MS/MS
Seventy protein spots were submitted for identification.
Among these, 57 spots were matched to the database,
and 29 proteins were successfully identified by MALDI-
TOF MS and MALDI-TOF/TOF MS/MS (Figure 2).
The results of protein identification via MALDI-TOF
MS, MS/MS and database research are listed in Table 1.
Some of these proteins were identified in several spots.
Validation of selected proteins by Western blot
To validate the results obtained in the proteomic study,
we selected two candidate proteins involved in angio-
genesis and vascular permeability (pigment epithelium-
derived factor and clusterin, which were significantly
underproduced in the vitreous fluid of PDR patients) to
be assessed by Western blot analysis. The band intensity
data were generated using the Phoretix 1D. As shown in
Figure 3, the PDR groups expressed significantly lower
levels of PEDF and clusterin compared with the control
when the data were analysed with the Mann-Whitney U
test (p < 0.01).
Discussion
This is the first report of a comparative proteomic analy-
sis of vitreous humour from type 2 diabetic patients with
PDR with that from normal human eyes donated for cor-
neal transplant. From the vitreous samples, we detected
more than a thousand spots at a time on a single gel
using DIGE; of these spots, 57 showed highly significant
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trol group and were successfully analysed as correspond-
ing to peptide fragments of 29 proteins, including 8
proteins that increased and 21 proteins that decreased in
PDR. Excluding the serum proteins from minor vitreous
haemorrhage, 19 proteins were identified as differentially
produced in the vitreous fluid of the PDR patients com-
pared with the vitreous fluid of the normal subjects; 6 of
these proteins have never been reported to be differen-
tially expressed in the PDR vitreous: N(G),N(G)-dimethy-
larginine dimethylaminohydrolase 1 (DDAH 1), tubulin
alpha-1B chain, gamma-enolase, cytosolic acyl coenzyme
A thioester hydrolase (ACOT1), malate dehydrogenase
(MDH) and phosphatidylethanolamine-binding protein 1
(PEBP1). The observed differences in PEDF and clusterin
levels by DIGE were further validated by western blot
analysis of the samples from each patient, which con-
firmed the observed differences with good quantitative
agreement. The results could not be extrapolated to the
other candidates because they have not been verified by
Western blot analysis.
Some of the identified proteins appeared at multiple
positions on the gels in this and other studies [6,16],
which is consistent with the presence of different post-
translationally modified forms. Post-translational modifi-
cations can change the MW and the pI of proteins, and
Figure 1 2-D DIGE images of the master gel (gel 1) and a graph view of spot 599.( A) Cy2 image from the internal standard. (B)C y 3
image from the control group. (C) Cy5 image from the PDR group. (D) The graph view showed the standardised abundance for spot 599 using
DeCyder analysis. The blue line links the average abundance values for each group of samples. (E) 3D simulation view of DeCyder analysis for
spot 599 in the control group. (F) 3D simulation view of DeCyder analysis for spot 599 in the PDR group.
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ferent spots. The quantification of the identified proteins
was based on the intensities from multiple spots.
PEDF is produced by the retinal pigment epithelium
and serves as a major inhibitor of intraocular angiogen-
esis. There is growing evidence to suggest that PEDF
has a modulatory role in angiogenesis [17]. PEDF altera-
tions in patients with PDR compared with nondiabetic
patients are controversial. Some previous studies pointed
to reductions in the levels of vitreous PEDF in patients
suffering from PDR [6,18-20]. Conversely, elevated levels
of PEDF were detected in some studies [13,21]. We
have detected reduced levels of PEDF in the vitreous
fluid of diabetic patients with PDR by both proteomic
analysis and Western blotting. PEDF might be candidate
target protein for diabetic retinopathy treatment.
Clusterin is a secreted glycoprotein that has been
implicated in a variety of physiological processes, includ-
ing cell-cell interaction, lipid transport, tissue remodel-
ling, chaperone activity, and apoptosis [22,23]. In recent
years, clusterin has been considered a potential diagnos-
tic and prognostic biomarker for several human cancers
[24-27]. An and colleagues have demonstrated that clus-
terin is produced and secreted by retinal pigment
epithelial (RPE) cells [28]. Previous studies suggest that
during diabetes-induced retinal damage, cytoplasmic
clusterin is likely to be associated with protection from
cell death, while nuclear clusterin might promote cell
Figure 2 Identification of proteins by MS and MS/MS. As an example, the identification of phosphatidylethanolamine-binding protein 1 is
represented here. The protein from spot 1010 was excised from the gels and digested with trypsin, and the resulting peptides were analysed
using a MALDI-TOF/TOF mass spectrometer. (A) The MS spectrum and (B) the MS/MS spectrum for the peptide CDEPILSNR. (C) The MS/MS
spectrum for the peptide LYTLVLTDPDAPSR. (D) The MS/MS spectrum for the peptide GNDISSGTVLSDYVGSGPPK. The chart represents m/z
(horizontal) versus intensity (vertical). The spectra for the tryptic peptides of PEBP 1 were annotated using the GPS explorer software, v3.6 and
the Mascot search engine, v2.1 with the UniprotKB/SwissProt database.
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Spot
no.(a)
Protein name Swiss-Prot
Access
Biological process Theoretical Observed Mascot
Score(b)
Matched
peptides
Ratio
PDR: C(c)
MW
(Da)
PI MW
(kDa)
PI
437 Ig alpha-1 chain C P01876 immune response 37630 6.08 63 6.4 281 9 5.45
441 region 63 6.0 366 13 4.29
443 62 6.2 356 11 3.61
467 63 5.8 364 10 3.39
500 70 6.5 143 6 -13.51
486 Tubulin alpha-1B chain P68363 microtubule-based
movement
50119 4.94 67 6.9 100 10 2.36
520 Keratin, type II P35908 keratinisation 65393 8.07 60 6.6 344 11 2.01
740 cytoskeletal 2 40 6.8 454 13 -7.87
838 epidermal 33 7.6 102 6 3.11
844 32 7.2 72 8 3.14
536 Complement factor I P05156 immune response 65677 7.72 61 6.7 116 8 2.29
537 Beta-crystallin B1 P53674 visual perception 28006 8.59 62 6.8 101 7 2.89
603 60 5.2 120 7 -2.55
645 45 7.8 127 8 -5.77
573 Hemopexin P02790 transport 51643 6.55 62 7.1 239 10 3.31
578 Cathepsin D P07339 proteolysis 44524 6.1 48 5.5 592 19 -3.24
585 49 5.6 361 18 -2.85
580 Pigment P36955 cell proliferation; 46313 5.97 50 5.7 119 6 -2.92
598 epithelium-derived negative regulation of
angiogenesis;
47 5.8 194 7 -2.96
599 factor (PEDF) positive regulation of
neurogenesis
60 6.2 339 11 -3.36
600 Gamma-enolase P09104 glycolysis 47239 4.91 60 5.2 625 19 -25.63
639 Zinc-alpha-2- P25311 fatty acid binding; 33851 6.45 45 5.2 251 12 3.52
654 glycoprotein ribonuclease activity 43 5.4 150 13 2,99
667 43 5.3 394 17 4.65
689 Cytosolic acyl coenzyme A
thioester hydrolase
O00154 hydrolysis 41769 8.85 40 7.6 134 7 -7.16
725 Ig heavy chain V-lll region BRO P01766 immune response 13218 6.45 42 6.1 101 3 -6.14
726 N(G),N(G)-dimethylarginine
dimethylaminohydrolase 1
O94760 arginine catabolic
process;
signal transduction
31102 5.53 43 5.8 65 5 -6.74
736 Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)
P04406 glycolysis 36030 8.57 37 8.3 308 11 -30.90
755 Clusterin P10909 apoptosis; 52461 5.89 38 4.8 521 19 -3.43
763 immune response 40 4.5 314 12 -2.56
766 38 5.1 284 15 -2.21
797 34 5.5 114 2 -3.92
800 35 5.9 221 10 -2.24
765 Malate dehydrogenase P40925 tricarboxylic acid cycle 36403 6.91 38 7.3 199 4 -4.74
794 Keratin, type I P35527 intermediate filament
organisation
62027 5.14 33 5.6 221 16 -2.20
1078 cytoskeletal 9 17 8.5 134 8 -14.34
838 Carbonic P00918 dehydratase activity; 29228 6.87 32 8.2 223 8 3.11
854 anhydrase 2 32 7.6 136 4 3.54
855 zinc ion binding 33 7.7 390 13 3.13
845 Keratin, type II cytoskeletal 6A P02538 structural constituent of
cytoskeleton
60008 8.09 33 7.4 82 11 3.23
930 Ig lambda-1 chain C regions P01842 immune response 11230 6.92 30 5.6 95 4 -2.61
942 Prostaglandin-H2 P41222 biosynthesis; 21015 7.66 28 4.9 91 4 -2.53
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990 D-isomerase transport 28 5.1 88 5 -3.32
974 Beta-crystallin S P22914 structural constituent of
eye lens
20993 6.44 28 6.8 147 4 -27.42
978 26 7.5 231 8 -24.32
1019 25 7.2 271 10 -57.43
982 Glutathione peroxidase 3 P22352 hydrogen peroxide
catabolic process;
oxidation/reduction
25537 8.26 27 5.9 256 6 -2.49
984 Beta-crystallin B2 P43320 visual perception 23365 6.50 27 8.0 113 5 -15.21
1010 Phosphatidylethanolamine-
binding protein 1
P30086 protease inhibitor 21044 7.01 28 8.3 437 12 -39.30
1015 Alpha-crystallin B chain P02511 anti-apoptosis;
muscle contraction;
intracellular transport;
protein folding;
protein
homooligomerisation;
response to heat
20146 6.76 26 7.8 283 9 -26.80
1049 Beta-crystallin A4 P53673 visual perception 22360 5.83 20 6.5 137 5 -5.70
1021 Beta-crystallin A3 P05813 visual perception 25134 5.81 25 6.8 483 12 -109.74
1022 23 7.9 428 11 -149.26
1023 24 7.5 351 12 -233.49
1024 Gamma-crystallin C P07315 visual perception 20865 6.88 23 7.8 395 12 -147.83
(a) In most cases, multiple spots correspond to the same protein.
(b) Probability-based MOWSE score. Scores higher than 64 indicate the level of statistical significance at p < 0.05.
(c) Abundance ratio between the different samples. A ratio > 2 or < -2 indicates statistical significance at p < 0.01. The fold-change of downregulation is shown
as a negative number, and the fold-change of upregulation is shown as a positive number.
Figure 3 Validation of the downregulation of clusterin and PEDF in the PDR vitreous by Western blot analysis.( A) Western blot analyses
of vitreous samples showing lower levels of PEDF (50 kDa) and clusterin (33 kDa) in the vitreous fluid of ten PDR patients. C (control group), P
(PDR group), and M (marker). (B) and (C) Densitometric analyses of the vitreous PEDF and clusterin levels. Vitreous PEDF and clusterin levels in
the PDR group were lower than those of the control group. (p < 0.01).
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TGF-b type II receptor (Tb R II) [30], and TGF-b plays
multifunctional roles in regulating the cell cycle, apopto-
sis, differentiation, and extracellular matrix remodelling
[31]. Clusterin is also an important mediator of cell sig-
nalling; it can interfere with NF-B, PI3 kinase, or MAP
kinase signalling [32,33], which are associated with cell
apoptosis and cell proliferation. In a mouse model of
DR, clusterin reduced the leakage from vessels in the
diabetic retina, which was accompanied by the restora-
tion of the expression of tight junction proteins [34,35].
These observations suggested that clusterin may play an
important role in the prevention of diabetes-induced
BRB breakdown. Our data show the downregulation of
clusterin in the PDR vitreous, which was confirmed by
Western blotting; however, the function of clusterin in
the vitreous is not yet clear. PDR is characterised by
neovascularisation and enhanced vascular permeability.
The proteins involved in the regulation of cell prolifera-
tion, apoptosis and BRB breakdown may play important
roles in PDR pathogenesis. Therefore, clusterin may
contribute to the pathogenesis of PDR, and further stu-
dies investigating the precise role of clusterin in diabetic
retinopathy are needed.
Carbonic anhydrase (CA) has been identified by pro-
teomic analysis in the vitreous humour from PDR
patients; CA production was increased in the vitreous of
diabetic retinopathy patients compared with the controls
[7,8]. In this study, we have confirmed this finding. The
presence of CA was initially thought to be due to retinal
haemorrhage and erythrolysis, but subsequent investiga-
tion demonstrated that CA is also actively involved in
the progression of diabetic retinopathy; CA-1 expression
leads to the activation of the contact system, the intrin-
sic pathway of coagulation, and promotes retinal vessel
leakage and intraretinal edema via increased kallikrein
activity [8]. The mechanisms involved in the increasing
production of CA and the value of CA to potential ther-
apeutic targets require further investigation.
In this study, we identified six proteins that have not
previously been reported or described in PDR. It is note-
worthy that four of them (DDAH, gamma-enolase, cyto-
solic acyl coenzyme A thioester hydrolase and malate
dehydrogenase) are cellular enzymes, and their levels are
all decreased in the vitreous of diabetic patients with
PDR, but we do not know whether these changes repre-
sent primary causes or consequences of PDR. DDAH is
an extremely oxidant-sensitive enzyme [36]. Decreased
DDAH expression/activity is evident in disease states
associated with endothelial dysfunction and is believed
to be the mechanism responsible for the increase in
methylarginine levels and the subsequent asymmetric
dimethylarginine (ADMA)-mediated endothelial nitric
oxide synthase impairment [37,38]. It should be noted
that vascular endothelial cells are major targets of
hyperglycaemic damage; endothelial dysfunction and
reduced levels of endothelial progenitor cells can cause
microvascular complications in diabetes mellitus [39,40].
Additionally, oxidative stress appears to play an impor-
tant role in endothelial dysfunction in diabetes. There-
fore, it is thought that the DDAH/ADMA pathway can
potentially modulate NO production and endothelial
function in PDR. In addition, gamma-enolase has been
found in different types of human cancer and is used as
a marker for tumoural or cellular damage [41,42].
Gamma-enolase is also used as a marker for neural
damage and is a reliable marker for cellular stress dur-
ing rhegmatogenous retinal detachment (RRD) [43,44].
The changed expression levels of cytosolic acyl coen-
zyme A thioester hydrolase and malate dehydrogenase
in the PDR vitreous could reflect the alterations in glu-
cose and lipid metabolism [45,46]. Moreover, acyl-CoA
thioesterases are highly regulated by peroxisome prolif-
erator-activated receptors (PPARs) [47], and PPARg ago-
nists have shown promise as targets in animal models of
proliferative retinopathies [48]. Further studies investi-
gating the role of these enzymes in diabetic retinopathy
are needed.
PEBP is a protease inhibitor, and it has been demon-
strated to bind to Raf-1 and mitogen-activated protein
kinase (MAPK), components of the extracellular signal-
regulated protein kinase (ERK) pathway [49]. Aberrant
signalling through the ERK pathway could promote cell
immortalisation via such mechanisms as telomerase
induction, growth factor-independent proliferation, and
angiogenesis by the upregulation of proangiogenic fac-
tors [50]. Therefore, the lower levels of PEBP detected
in PDR patients are perhaps related to neovascularisa-
tion and cell cycle progression.
Several types of crystallins, including beta-crystallin S,
beta-crystallin B2, alpha-crystallin B chain, beta-crystal-
lin A4, beta-crystallin A3, and gamma-crystallin C, were
found in the vitreous humour of both PDR patients and
controls. All types of crystallins found in this study were
significantly lower in the vitreous humour from PDR
patients compared with that from the control subjects,
and a previous study has reported that beta-crystallin B2
was identified by MALDI-TOF in normal vitreous [12].
We do not know why the crystallin levels are decreased
in the vitreous of diabetic patients with PDR; the biolo-
gical functions of crystallins are not completely under-
stood. However, it is noteworthy that aA-crystallin and
advanced glycation end product (AGE) were highly
expressed in human diabetic retinas, and aA-crystallin
expression was up-regulated in murine posterior eye-
cups after recombinant AGE protein was injected into
the vitreous of adult murine eyes, aA-crystallin
responded to AGE accumulation, which may contribute
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retinal tissue injury [51]. Thus, the mechanisms involved
in the intraocular production of crystallins and the role
of crystallins in the pathogenesis of PDR require further
investigation.
There are two main limitations to this study. First, the
gel electrophoresis technique has a number of signifi-
cant drawbacks. These include its inability to detect
low-abundance proteins in the presence of high-abun-
dance proteins or to separate proteins that are too basic,
too acidic, too large, or too small [52,53]. Thus, the
detection shortcoming may be responsible for our fail-
ure to detect vascular endothelial growth factor (VEGF),
a key mediator of retinal neovascularisation and vascular
permeability in the pathogenesis of diabetic retinopathy
[54]. We will apply other proteomic technologies in an
effort to pursue this issue. Second, vitreous haemorrhage
that occurs in PDR can produce a massive influx of
serum proteins. Although we excluded any samples dis-
playing gross vitreous haemorrhage, our results also
included some serum proteins resulting from minor
vitreal haemorrhage or leakage of serum into the
vitreous.
Conclusions
In this study, we identified 19 proteins in the human vitr-
eous, the expression levels of which were either signifi-
cantly attenuated or augmented in PDR patients.
Clusterin, a potent protective factor in BRB breakdown,
was downregulated in the PDR vitreous. Moreover, we
identified six proteins, which may be related to endothe-
lial dysfunction, neovascularisation and cell-cycle pro-
gression, that have not been previously reported or
described in PDR. From the perspective of our study, it is
most advantageous and desirable if those differentially
e x p r e s s e dp r o t e i n sa l s ol e a dt o w a r dam o r ec o n c r e t e
understanding of pathogenesis and therapeutic targets
for proliferative diabetic retinopathy.
Methods
Study subjects and sample collection
Vitreous fluid was obtained from individuals with prolif-
erative diabetic retinopathy (n = 10) undergoing pars
plana vitrectomies at the Shanghai Tenth People’s Hospital
and the Fudan University Affiliated Eye and ENT Hospital
in accordance with the approved Human Discarded Speci-
men Research Protocols from the institutional review
boards. Undiluted vitreous samples (0.5-1.0 ml) were col-
lected at the time of vitrectomy before opening the infu-
sion line. The exclusion criteria were as follows: (1) a
history of ocular surgery; (2) gross vitreous haemorrhage
or a history of recent vitreous haemorrhage; (3) other ocu-
lar diseases such as retinal vein occlusion and age-related
macular degeneration; and (4) other systemic diseases
aside from diabetes. The control group, consisting of vitr-
eous fluid from normal human eyes without any known
ocular diseases (n = 10) that were donated for corneal
transplant, were obtained from the Red Cross Eye Bank of
Shanghai in China in accordance with the Standardized
Rules for the Development and Applications of Organ
Transplants. The normal vitreous samples (0.8-1.0 ml)
were aspirated with a syringe at the pars plana. The undi-
luted vitreous samples were collected in tubes and frozen
at -80°C until they were required. There was no significant
difference in the ages (48.8 ± 11.3 vs. 49.7 ± 8.6; p =n s )
and the percentage of male subjects (20% vs. 70%, Fischer’s
exact test, p = 0.07) between the diabetic patients and the
donors of the control samples.
The research was conducted in accordance with the
tenets of the Declaration of Helsinki. The research pro-
tocol was approved by the hospital ethics committee,
and informed consent was obtained from the patients.
Vitreous sample preparation
The vitreous samples were lysed at room temperature and
subsequently solubilised in lysis buffer (7 M urea, 2 M
thiourea, 10 mM DTT, 150 mM Tris, and one complete
proteinase inhibitor cocktail tablet per 50 ml lysis buffer)
for 30 min. After sonication, the samples were centrifuged
at 40000× g for 1 h at 4°C, and the supernatant was sub-
jected to methanol/chloroform precipitation. After the pel-
lets were dried, they were resuspended in lysis buffer.
Next, the protein concentrations were determined using
BioRad protein assay reagents (BioRad Laboratories, Her-
cules, CA, USA) and stored at -80°C for subsequent analy-
sis. All chemical reagents were obtained from Sigma
Aldrich (St. Louis, MO, USA) unless otherwise noted.
Two-dimensional difference gel electrophoresis (2-D
DIGE)
To reduce the impact of the differences between the indi-
viduals, the vitreous samples in the same group were
mixed at the same volume before the experiment was
performed. The concentration of each sample was
adjusted to 5 μg/μl. Equal amounts of each of the sam-
ples were pooled to generate the internal standard. The
protein samples were minimally labelled with Cy Dye
according to the manufacturer’s recommended protocols
(GE Healthcare). Briefly, the soluble protein samples
from the PDR vitreous and control vitreous were labelled
with either Cy3 or Cy5 at pH 8-9. Cy2 was used to label
the pooled internal standard, which can compensate for
gel-to-gel variations. The labelling was performed by
adding 400 pmol of the required Cy Dye in 1 μl of anhy-
drous N,N-dimethylformamide per 50 μg of protein. The
labelling reaction was performed on ice in the dark for
30 min, and 1 μl of 10 mM lysine was added for 10 min
to terminate the labelling reaction.
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three samples labelled with Cy2, Cy3 and Cy5 were
pooled and mixed with rehydration buffer (2 M thiourea,
6Mu r e a ,4 %C H A P S ,2 0m MD T Ta n d0 . 2 5 %o fa n
appropriate immobilised pH gradient (IPG) buffer). The
samples were subsequently applied to IPG strips (13 cm,
pH 3-10) for passive rehydration. IEF was performed on
an Ettan IPGphor Isoelectric Focusing System(GE
Healthcare)at 20°C using the following program: 30 V for
12 h, 500 V for 1 h, 1000 V for 1 h, 8000 V for 8 h, and
500 V for 4 h.
After IEF, the strips were incubated for 15 min at
room temperature with equilibration buffer (50 mM
Tris, 6 M urea, 30% v/v glycerol, 2% w/v SDS and 2%
DTT) followed by a second incubation step in the same
buffer solution containing 2.5% iodoacetamide (GE
Healthcare) in place of the DTT.
Next, the strips were transferred to the second-dimen-
sion 12.5% SDS-PAGE and run on a Hofer SE 600 (GE
Healthcare) at 15 mA per gel for 20 min, followed by 30
mA for the remainder of the run until the dye front
reached the bottom of the gel. All electrophoresis proce-
dures (labelling, first dimension, and second dimension)
were performed in the dark.
After the proteins were separated, all gels were scanned
using a UMax Powerlook 2100XL (GE Healthcare). Cy2,
Cy3 and Cy5 images were scanned at excitation wave-
lengths of 488 nm, 532 nm, 633 nm, respectively. We
compared the protein abundances between two groups
with the ImageQuant and DeCyder v. 5.0 Software (GE
Healthcare); three individual 2-D DIGE experiments were
performed to obtain consistently detected spots.
Tryptic in-gel digestion
Protein spots were excised from the preparative gels and
destained with 100 mM NH4HCO3 in 30% ACN. After
removing the destaining buffer, the gel pieces were lyophi-
lised and rehydrated in 30 μlo f5 0m MN H 4HCO3 con-
taining 50 ng trypsin (sequencing grade; Promega,
Madison, WI, USA). After overnight digestion at 37°C, the
peptides were extracted three times with 0.1% TFA in 60%
ACN. The extracts were pooled and lyophilised. The
resulting lyophilised tryptic peptides were stored at -80°C
until mass spectrometric analysis. A protein-free gel piece
was treated as above and used for a control to identify
autoproteolytic products derived from trypsin.
Protein identification by MALDI-TOF MS and MS/MS
MS and MS/MS spectra were obtained using an Applied
Biosystems 4700 Proteomics Analyzer (Foster City, CA,
USA). The MALDI-TOF/TOF instrument was operated
in a result-dependent acquisition mode. Peptide mass
maps were acquired in the positive ion reflector mode
(20 kV accelerating voltage) with 1000 laser shots per
spectrum. Monoisotopic peak masses were automatically
determined within the mass range of 800-4000 Da with a
signal-to-noise ratio minimum set to 10 and a local noise
window width of m/z 250. The 5 most intense peptides
with signal-to-noise ratios exceeding 50 were subjected
to MS/MS. The MS and MS/MS spectra were searched
against the UniprotKB/SwissProt database (v. 2010.03.02,
release number: 15.15/57.15) using the GPS Explorer
software, version 3.6 (Applied Biosystems) and the Mas-
cot search engines, version 2.1 (Matrix Science, Boston,
MA) with the following parameter settings: one missed
tryptic cleavage event allowed, carbamidomethylation set
as a fixed modification, oxidation of methionines allowed
as a variable modification, peptide mass tolerance set to
100 ppm, fragment tolerance set to ± 0.3 Da, and the
minimum ion score confidence interval for MS/MS data
set to 95%. Only identified proteins with a protein score
confidence index (CI) > 95% were accepted. In the case
that shared peptides mapped to more than one protein
identifier (ID), the ID with the higher protein score was
retained. If multiple IDs had the same protein score, the
ID with the larger number of peptides was retained.
Western blot analysis
To confirm changes in specific proteins, immunoblotting
was performed on the 20 vitreous samples used in the
DIGE experiments. For normalisation purposes, equal
amounts (10 μg) of soluble protein from each vitreous
sample were applied to each lane on a 12% acrylamide gel
and subsequently electrophoretically transferred to a poly-
vinylidene fluoride transfer membrane (Hybond-C; Amer-
sham Biosciences Inc., Arlington Heights, IL) at 50 mV for
1.5 h. The membranes were blocked with 5% BSA (w/v)
for 1 h at room temperature and incubated overnight at
4°C with primary mouse monoclonal antibodies raised
against the full-length recombinant PEDF (50 kDa) and
clusterin (33 kDa) of human origin (Santa Cruz Biotech-
nology, Inc.), diluted 1:3000 and 1:8000, respectively. The
blots were washed with TBS-T (0.1% Tween-20 in TBS)
three times before incubation with the secondary antibody
(horseradish peroxidase-conjugated goat anti-rabbit IgG,
1:5000, Pierce) for 1 h at room temperature. The hybri-
dised membrane was washed in TBS-T buffer and visua-
lised using an ECL Western Blotting Kit (GE Healthcare).
Statistical analysis
The results obtained for each of the differentially
expressed protein spots on the 2-D DIGE gels were ana-
lysed statistically using the independent t test, and the
Western blot intensity data between the groups were
compared with the Mann-Whitney U test using the
SPSS 14.0 statistics package (SPSS, Chicago, IL, USA). A
p value of less than 0.01 was considered statistically
significant.
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